ArticleCancer biology & medicine2025
Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy.
Shuyi Hu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.